Stock AUPH AURINIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
5.76 USD -0.17% Intraday chart for Aurinia Pharmaceuticals Inc. +11.41% -35.93%
May. 14 Aurinia Pharmaceuticals Inc. Presented Results from the Analysis Showing Lupkynis A Cost-Effective Treatment for Lupus Nephritis Presented At National Kidney Foundation's Spring Clinical Meeting 2024 CI
May. 07 Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aurinia Pharmaceuticals Inc. Presented Results from the Analysis Showing Lupkynis A Cost-Effective Treatment for Lupus Nephritis Presented At National Kidney Foundation's Spring Clinical Meeting 2024
CI
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
BU
AURINIA PRESENTS DATA REINFORCING LUPKYNIS SAFETY AND EFFICACY FOR PEOPLE WITH LUPUS NEPHRITIS AT CONGRESS OF CLINICAL RHEUMATOLOGY EAST 2024
AQ
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
BU
Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value
CI
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
BU
Transcript : Aurinia Pharmaceuticals Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q1 Revenue $50.3M, vs. Street Est of $47.1M
MT
Aurinia: Q1 Earnings Snapshot
AQ
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
BU
Aurinia Pharmaceuticals Inc. Reiterates Revenue Guidance for the Fiscal Year 2024
CI
AURINIA PHARMACEUTICALS - THE U.S. FOOD & DRUG ADMINISTRATION APPROVES UPDATED LUPKYNIS LABEL TO INCLUDE LONG-TERM DATA FROM THE AURORA CLINICAL PROGRAM
AQ
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
BU
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
BU
Aurinia Pharmaceuticals Inc. Announces The U.S. Food & Drug Administration Approves Updated LUPKYNIS® Label to include Long-Term Data from the AURORA Clinical Program
CI
UPDATE, NEW AURINIA PRESENTATION DETAILS AT THE 2024 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE
AQ
New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
BU
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
BU
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AUPH Stock
  4. News Aurinia Pharmaceuticals Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW